Clinical trials: sponsored by iOMEDICO AG
Metastatic Breast Cancer
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
AIM OF STUDY Primary Efficacy Variable: The primary study objective is the proof of efficacy, measured by progression free survival (PFS) in the treatment of metastatic or locally inoperable recurrent breast cancer.
- Trial name
- PASO (NCT01320111)
- Testing
- Paclitaxel and Sorafenib, Paclitaxel
- Where
- Germany
- Volunteers
- 59 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Metastatic Breast Cancer
Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer
The aim of the trial is to detect the superiority of the triple combination of capecitabine, bevacizumab and vinorelbine versus the combination of capecitabine and bevacizumab in patients with metastatic breast cancer.
- Trial name
- CARIN (NCT00868634)
- Testing
- capecitabine, bevacizumab, vinorelbine
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- iOMEDICO AG
Anemia
Clinical Tumor Anemia Registry (TAR)
The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided.
- Trial name
- TAR (NCT01795690)
- Where
- Germany
- Volunteers
- 1,018 people
- Sponsor
- iOMEDICO AG
MDS, AML
Non-interventional Study With Azacitidin (Vidaza®)
The purpose of this non-interventional study is to collect data on the efficiency and safety of Azacitidin in the routine application.
- Conditions
- MDS, AML, CMMOL
- Trial name
- Piaza (NCT01192945)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- iOMEDICO AG
Antiemetic Therapy
Epidemiological EMESIS-Registry
The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major…
- Trial name
- EMESIS (NCT00911222)
- Testing
- non-interventional
- Where
- Germany
- Volunteers
- 1,035 people
- Sponsor
- iOMEDICO AG
Metastatic Breast Cancer, HER2 Positive
Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer
The purpose of the study is to investigate safety and efficiency of the triple combination of capecitabine, lapatinib and vinorelbine in patients with metastatic breast cancer.
- Conditions
- Metastatic Breast Cancer, HER2 Positive, First or Second Line Therapy, Failure or Contraindication of Trastuzumab Therapy
- Trial name
- CELAVIE (NCT01238029)
- Testing
- Lapatinib and Capecitabine and Vinorelbine
- Where
- 11 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Sponsor GmbH
Renal Cell Carcinoma
Sequential Study to Treat Renal Cell Carcinoma
Primary: To evaluate if progression-free survival from first treatment to progression or death during second-line therapy (total PFS) of sorafenib followed by sunitinib is superior compared to sunitinib followed by sorafenib.
- Trial name
- NCT00732914
- Testing
- Sunitinib (Sutent), Sorafenib (Nexavar)
- Where
- Germany
- Volunteers
- 272 people
- Sponsor
- Sponsor GmbH
Colorectal Neoplasms
Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer
The purpose of this interventional study is to investigate whether there is evidence that panitumumab in combination with XELOX (capecitabine plus oxaliplatin) chemotherapy will safely increase progression-free survival, above…
- Trial name
- VOXEL (NCT00950820)
- Testing
- Oxaliplatin, Capecitabine, Panitumumab, Oxaliplatin, Capecitabine
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- AIO-Studien-gGmbH
Non Small Cell Lung Carcinoma, Metastatic Breast Cancer
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
The purpose of this non-interventional study is to collect data on efficacy and toxicity of the use of Navelbine ORAL in daily routine in Germany (especially after availability of an 80mg capsule).
- Trial name
- NCT00890903
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Pierre Fabre Pharma GmbH